Search research articles
Contact Us
Filters
Showing results (61-70 of 99) with videos related to
Page
of 10
Sort By:
Clinical Cardiology
|
January 12, 2022
Early and late recurrent cardiovascular events among high-risk patients with an acute coronary syndrome: Meta-analysis of phase III studies and implications on trial design
Gerald Chi, Jane J Lee, Syed H A Kazmi, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions
|
September 13, 2019
Procedural, clinical, and health status outcomes in chronic total coronary occlusion revascularization: Results from the PERSPECTIVE study
David E Kandzari, Nicholas J Lembo, Harold D Carlson, et al.
Research and Practice in Thrombosis and Haemostasis
|
February 29, 2020
Machine learning to predict venous thrombosis in acutely ill medical patients
Tarek Nafee, C Michael Gibson, Ryan Travis, et al.
European Heart Journal. Cardiovascular Pharmacotherapy
|
February 14, 2023
Biological basis and proposed mechanism of action of CSL112 (apolipoprotein A-I [human]) for prevention of major adverse cardiovascular events in patients with myocardial infarction
Serge Korjian, Syed Hassan A Kazmi, Gerald Chi, et al.
American Heart Journal
|
April 15, 2018
Symptomatic event reduction with extended-duration betrixaban in acute medically ill hospitalized patients
C Michael Gibson, Tarek Nafee, Megan K Yee, et al.
TH Open : Companion Journal to Thrombosis and Haemostasis
|
June 29, 2019
The IMPROVEDD VTE Risk Score: Incorporation of D-Dimer into the IMPROVE Score to Improve Venous Thromboembolism Risk Stratification
C Michael Gibson, Alex C Spyropoulos, Alexander T Cohen, et al.
Journal of the American Heart Association
|
July 13, 2017
Comparison of Fatal or Irreversible Events With Extended-Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients: An APEX Trial Substudy
C Michael Gibson, Serge Korjian, Gerald Chi, et al.
American Heart Journal
|
June 16, 2026
The Effect of Zalunfiban on High Sensitivity Cardiac Troponin and the Association with Clinical Outcomes in Patients with STEMI
James L Januzzi, C Michael Gibson, Gerald Chi, et al.
Journal of Cardiovascular Pharmacology and Therapeutics
|
October 25, 2022
CSL112 (Apolipoprotein A-I [Human]) Strongly Enhances Plasma Apoa-I and Cholesterol Efflux Capacity in Post-Acute Myocardial Infarction Patients: A PK/PD Substudy of the AEGIS-I Trial
C Michael Gibson, Syed Hassan A Kazmi, Serge Korjian, et al.
Medrxiv : the Preprint Server for Health Sciences
|
February 23, 2026
The Effect of Zalunfiban on High Sensitivity Cardiac Troponin and the Association with Clinical Outcomes in Patients with STEMI
James L Januzzi, C Michael Gibson, Gerald Chi, et al.
Page
of 10
Search research articles
Search
Showing results (61-70 of 99) with videos related to
Sort By:
Page
of 10
Clinical Cardiology
|
January 12, 2022
Early and late recurrent cardiovascular events among high-risk patients with an acute coronary syndrome: Meta-analysis of phase III studies and implications on trial design
Gerald Chi, Jane J Lee, Syed H A Kazmi, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions
|
September 13, 2019
Procedural, clinical, and health status outcomes in chronic total coronary occlusion revascularization: Results from the PERSPECTIVE study
David E Kandzari, Nicholas J Lembo, Harold D Carlson, et al.
Research and Practice in Thrombosis and Haemostasis
|
February 29, 2020
Machine learning to predict venous thrombosis in acutely ill medical patients
Tarek Nafee, C Michael Gibson, Ryan Travis, et al.
European Heart Journal. Cardiovascular Pharmacotherapy
|
February 14, 2023
Biological basis and proposed mechanism of action of CSL112 (apolipoprotein A-I [human]) for prevention of major adverse cardiovascular events in patients with myocardial infarction
Serge Korjian, Syed Hassan A Kazmi, Gerald Chi, et al.
American Heart Journal
|
April 15, 2018
Symptomatic event reduction with extended-duration betrixaban in acute medically ill hospitalized patients
C Michael Gibson, Tarek Nafee, Megan K Yee, et al.
TH Open : Companion Journal to Thrombosis and Haemostasis
|
June 29, 2019
The IMPROVEDD VTE Risk Score: Incorporation of D-Dimer into the IMPROVE Score to Improve Venous Thromboembolism Risk Stratification
C Michael Gibson, Alex C Spyropoulos, Alexander T Cohen, et al.
Journal of the American Heart Association
|
July 13, 2017
Comparison of Fatal or Irreversible Events With Extended-Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients: An APEX Trial Substudy
C Michael Gibson, Serge Korjian, Gerald Chi, et al.
American Heart Journal
|
June 16, 2026
The Effect of Zalunfiban on High Sensitivity Cardiac Troponin and the Association with Clinical Outcomes in Patients with STEMI
James L Januzzi, C Michael Gibson, Gerald Chi, et al.
Journal of Cardiovascular Pharmacology and Therapeutics
|
October 25, 2022
CSL112 (Apolipoprotein A-I [Human]) Strongly Enhances Plasma Apoa-I and Cholesterol Efflux Capacity in Post-Acute Myocardial Infarction Patients: A PK/PD Substudy of the AEGIS-I Trial
C Michael Gibson, Syed Hassan A Kazmi, Serge Korjian, et al.
Medrxiv : the Preprint Server for Health Sciences
|
February 23, 2026
The Effect of Zalunfiban on High Sensitivity Cardiac Troponin and the Association with Clinical Outcomes in Patients with STEMI
James L Januzzi, C Michael Gibson, Gerald Chi, et al.
Page
of 10